GlaxoSmithKline Pharma net profit rises 8 percent to Rs 116 crore in Q1
Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.
New Delhi: GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit increased by 8 per cent to Rs 116 crore in the first quarter ended on June 30, 2022.
The drug firm had reported a net profit of Rs 107 crore in the April-June quarter of the previous year.
Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.
Read also: GSK-Sanofi variant-specific COVID vaccine found effective against Omicron
"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands," GlaxoSmithKline Pharmaceuticals MD Sridhar Venkatesh noted..
The drug firm is a subsidiary of GSK plc, a global biopharma company.
Read also: GSK spins off consumer health business Haleon
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company headquartered in Mumbai, Maharashtra, India. The company was founded in 1924. Its product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.
